Anti-EGFR for left-sided, RAS wild-type metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread (metastatic) and cannot be removed by surgery.
- Your primary tumor is located on the left side of your colon.
- Your tumor does not have mutations in the KRAS or NRAS genes (RAS wild-type).
- You have not received any chemotherapy or targeted therapy for metastatic disease (prior treatments for early-stage cancer are allowed if finished at least 6 months ago).
- You are 18 or older, in generally good health (ECOG score 0-2), and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
This trial tests whether adding an anti-EGFR drug to standard chemotherapy helps people with right-sided advanced colorectal cancer that has not had chemotherapy before. You need to have a specific gene pattern (no RAS mutation and high AREG/EREG) to join.
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial tests two different combinations of chemotherapy drugs plus targeted therapy (cetuximab or bevacizumab) along with an immunotherapy drug (QL1706) as the first treatment for people with left-sided metastatic colorectal cancer that has no mutations in the KRAS, NRAS, or BRAF genes. The goal is to see which combination is more effective and safe.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
Hear when a new Chemotherapy Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.